Optimizing Therapy for Hairy Cell Leukemia

home / peer-exchange / hcl-optimizing-therapy

Hairy Cell Leukemia: Incidence and Presentation

EP. 1: Hairy Cell Leukemia: Incidence and Presentation

A Differential Diagnosis of Hairy Cell Leukemia

EP. 2: A Differential Diagnosis of Hairy Cell Leukemia

Approaches to Frontline Therapy in HCL

EP. 3: Approaches to Frontline Therapy in HCL

Monitoring Response & Initiating Second-Line Therapy in HCL

EP. 4: Monitoring Response & Initiating Second-Line Therapy in HCL

Anti-CD22 Therapy in HCL: Moxetumomab Pasudotox

EP. 5: Anti-CD22 Therapy in HCL: Moxetumomab Pasudotox

Moxetumomab Pasudotox for HCL: Managing Side Effects

EP. 6: Moxetumomab Pasudotox for HCL: Managing Side Effects

Hairy Cell Leukemia: Unmet Needs and Combination Strategies

EP. 7: Hairy Cell Leukemia: Unmet Needs and Combination Strategies

Parting Advice on Hairy Cell Leukemia Management

EP. 8: Parting Advice on Hairy Cell Leukemia Management

First-Line Therapy Options in Hairy Cell Leukemia

EP. 9: First-Line Therapy Options in Hairy Cell Leukemia

Indicators Prompting Treatment of HCL

EP. 10: Indicators Prompting Treatment of HCL

HCL Combination Therapy: Rituximab and Purine Analog

EP. 11: HCL Combination Therapy: Rituximab and Purine Analog

Concurrent vs Sequential Rituximab in HCL

EP. 12: Concurrent vs Sequential Rituximab in HCL

The Role of MRD in Treatment of HCL

EP. 13: The Role of MRD in Treatment of HCL

$Treating Relapsed/Refractory or Progressive HCL$

EP. 14: Treating Relapsed/Refractory or Progressive HCL

The Use of Splenectomy in HCL Treatment

EP. 15: The Use of Splenectomy in HCL Treatment

BRAF/MEK Inhibition in HCL Management

EP. 16: BRAF/MEK Inhibition in HCL Management

Non-Chemotherapy Agents & Anti-CD22 in HCL Treatment

EP. 17: Non-Chemotherapy Agents & Anti-CD22 in HCL Treatment

Moxetumomab Pasudotox in HCL

EP. 18: Moxetumomab Pasudotox in HCL

HCL Management: Recommendations and Advice

EP. 19: HCL Management: Recommendations and Advice

Latest Conference Coverage

Dr Jurczak on the Efficacy and Safety of Nemtabrutinib in R/R Follicular Lymphoma

Oral Revumenib-Based Combo Produces Responses in R/R AML

D-VRd Deepens MRD Responses in Transplant-Ineligible or -Deferred Newly Diagnosed Myeloma

Revumenib Displays Activity in Relapsed/Refractory KMT2Ar Acute Leukemias

View More Latest Conference Coverage

Editorial Board

MJH Life Sciences brands

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.